|
1) 胃潰瘍ガイドラインの適用と評価に関する研究班, 編. EBMに基づく胃潰瘍診療ガイドライン第2版. 東京: じほう; 2007
|
|
|
|
|
2) Miwa H, Sakaki N, Sugano K, et al. Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter. 2004; 9: 9-16
|
|
|
|
|
3) 那須 勝, 小林寅吉吉. わが国におけるHelicobacter pylori 耐性菌サーベイランス. Helicobacter Research. 2006; 12: 524-7
|
|
|
|
|
|
4) Hawkey CJ, Weinstein WM, Smalley W, et al. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Gastroenterology. 2007; 133: 57-64
|
|
|
|
|
|
5) Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005; 352: 1018-91
|
|
|
|
|
|
6) Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China. JAMA. 2004; 291: 187-94
|
|
|
|
|
|
7) Take S, Mizuno M, Ishiki K, et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 2005; 100: 1037-42
|
|
|
|
|